Summit (TM) 2.0 is a CSF-based liquid biopsy assay designed to enable comprehensive genomic profiling for characterization of CNS tumors. CNS malignancies present unique diagnostic challenges, as ...

By Hugo Francisco de Souza New neuroimaging research shows that when sleep-deprived people lose focus, the brain briefly ...

Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...

The world’s first AI-based optical diagnostic platform offers potential for near-instant diagnosis of CSF rhinorrhea.

Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022 Effective diagnosis, prognostication, ...

CRISPR/Cas9-Mediated GM-CSF knock-out (GM-CSF ko) CAR-T cells demonstrate reduced apoptosis and enhanced in vivo anti-tumor activity in preclinical models Phase 3 SHIELD study utilizing lenzilumab to ...

In a recent study published in Jama Network, researchers investigated the impact of coronavirus disease 2019 (COVID-19) on biomarkers in the cerebrospinal fluid (CSF). Study: Viral Antigen and ...

Pharaoh Neuro’s cerebrospinal fluid management system has already demonstrated positive prospective trial results.

The study covered in this summary was published in medRxiv.org as a preprint and has not yet been peer reviewed. Cerebrospinal fluid (CSF) inflammatory marker levels were found to be associated with ...

Understanding Barriers and Facilitators to High-Quality Cancer Care Among Veterans With Lung Cancer: A Qualitative Study We conducted a cluster-randomized trial among 32 oncology clinics from the NCI ...